[go: up one dir, main page]

HK1214968A1 - 用於非酒精性脂肪肝病 的新組合物 - Google Patents

用於非酒精性脂肪肝病 的新組合物

Info

Publication number
HK1214968A1
HK1214968A1 HK16103017.5A HK16103017A HK1214968A1 HK 1214968 A1 HK1214968 A1 HK 1214968A1 HK 16103017 A HK16103017 A HK 16103017A HK 1214968 A1 HK1214968 A1 HK 1214968A1
Authority
HK
Hong Kong
Prior art keywords
nafld
liver disease
fatty liver
novel composition
nonalcoholic fatty
Prior art date
Application number
HK16103017.5A
Other languages
English (en)
Inventor
Pankaj Patel
Jani Rajendrakumar Hariprasad
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of HK1214968A1 publication Critical patent/HK1214968A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK16103017.5A 2013-04-22 2016-03-15 用於非酒精性脂肪肝病 的新組合物 HK1214968A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
IN1468MU2013 IN2013MU01468A (zh) 2013-04-22 2013-06-25

Publications (1)

Publication Number Publication Date
HK1214968A1 true HK1214968A1 (zh) 2016-08-12

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103017.5A HK1214968A1 (zh) 2013-04-22 2016-03-15 用於非酒精性脂肪肝病 的新組合物

Country Status (21)

Country Link
US (3) US20160166539A1 (zh)
EP (1) EP2988736A1 (zh)
JP (1) JP6246895B2 (zh)
KR (1) KR101617812B1 (zh)
CN (1) CN105377246B (zh)
AP (1) AP2015008674A0 (zh)
AU (1) AU2013387996B2 (zh)
BR (1) BR112015020600A2 (zh)
CA (1) CA2900435C (zh)
EA (1) EA201592020A1 (zh)
GE (1) GEP201706663B (zh)
HK (1) HK1214968A1 (zh)
IL (2) IL240183A (zh)
IN (1) IN2013MU01468A (zh)
MA (1) MA38385A1 (zh)
MX (1) MX346943B (zh)
MY (1) MY180160A (zh)
PH (1) PH12015501795A1 (zh)
SG (1) SG11201506218UA (zh)
UA (1) UA114360C2 (zh)
WO (1) WO2014174524A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110813C2 (uk) 2011-01-31 2016-02-25 Каділа Хелткере Лімітед Лікування ліподистрофії
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
KR101617812B1 (ko) 2013-04-22 2016-05-03 카딜라 핼쓰캐어 리미티드 비알콜성 지방간 질환을 위한 신규 조성물
WO2014195967A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (zh) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (zh) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2018104916A1 (en) * 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
CA3077273A1 (en) * 2017-10-06 2019-04-11 Gilead Sciences, Inc. Combination therapy comprising an acc inhibitor
CN109675016A (zh) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 非酒精性脂肪性肝病的治疗药物
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US12201609B2 (en) * 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
EP3923932A4 (en) * 2019-02-13 2022-11-16 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
US20220378786A1 (en) * 2021-05-21 2022-12-01 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0648212B1 (en) 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
TW480262B (en) 1995-04-28 2002-03-21 Daiichi Seiyaku Co A taxol derivative having an antitumor activity and a pharmaceutical composition comprising the same
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6130214A (en) 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
ATE286032T1 (de) 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
NZ504106A (en) 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
JP2002527520A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用
AU6325899A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
JP2002527516A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
DK1250323T3 (da) 2000-01-19 2014-02-03 Cadila Healthcare Ltd Forbindelser med hypolipidemiske og hypokolesterolemiske virkninger, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
WO2007035771A2 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Modulation of glucagon receptor expression
EP2069380B1 (en) * 2006-09-18 2014-11-12 Alnylam Pharmaceuticals Inc. Rnai modulation of scap and therapeutic uses thereof
JP2008184429A (ja) * 2007-01-30 2008-08-14 Japan Health Science Foundation 肝臓トリグリセリド濃度低下剤
CA2781451C (en) 2009-11-26 2019-04-16 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
MX2013004123A (es) 2010-10-12 2013-12-16 Univ Johns Hopkins Composiciones antitusigenas que comprenden memantina.
UA110813C2 (uk) * 2011-01-31 2016-02-25 Каділа Хелткере Лімітед Лікування ліподистрофії
KR101617812B1 (ko) 2013-04-22 2016-05-03 카딜라 핼쓰캐어 리미티드 비알콜성 지방간 질환을 위한 신규 조성물
WO2014195967A2 (en) 2013-05-30 2014-12-11 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (zh) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015029066A1 (en) 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (zh) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
US20170087127A1 (en) 2017-03-30
IL240183A (en) 2016-08-31
IL240183A0 (en) 2015-09-24
KR20150118990A (ko) 2015-10-23
JP2016515608A (ja) 2016-05-30
IN2013MU01468A (zh) 2015-04-17
US20160166539A1 (en) 2016-06-16
EA201592020A1 (ru) 2016-05-31
WO2014174524A1 (en) 2014-10-30
CA2900435C (en) 2017-02-14
GEP201706663B (en) 2017-05-10
US9814697B2 (en) 2017-11-14
JP6246895B2 (ja) 2017-12-13
AU2013387996B2 (en) 2015-12-10
AU2013387996A1 (en) 2015-09-24
WO2014174524A8 (en) 2015-10-01
MX2015010769A (es) 2015-11-26
CN105377246A (zh) 2016-03-02
KR101617812B1 (ko) 2016-05-03
CA2900435A1 (en) 2014-10-30
BR112015020600A2 (pt) 2017-07-18
UA114360C2 (uk) 2017-05-25
US20180185330A1 (en) 2018-07-05
MA38385A1 (fr) 2017-09-29
PH12015501795A1 (en) 2015-11-09
SG11201506218UA (en) 2015-09-29
AP2015008674A0 (en) 2015-08-31
EP2988736A1 (en) 2016-03-02
MX346943B (es) 2017-04-06
IL247231A (en) 2017-03-30
MY180160A (en) 2020-11-23
CN105377246B (zh) 2018-03-20

Similar Documents

Publication Publication Date Title
HK1214968A1 (zh) 用於非酒精性脂肪肝病 的新組合物
IL279395A (en) A vaccine
HK1220251A1 (zh) 非酒精性脂肪性肝病 和非酒精性脂肪性肝炎 的生物標記物及其用途
EP3006511A4 (en) VULCANIZABLE COMPOSITION
EP2979681A4 (en) CURABLE COMPOSITION
IL244406A0 (en) A multi-part acrylic preparation that can be hardened
PL2839750T3 (pl) Kompozycja tłuszczowa
AU352808S (en) Dispenser for curable compositions
GB201317105D0 (en) Novel Composition
IL244407A0 (en) A multi-part acrylic preparation that can be hardened
HK1218877A1 (zh) 粘膜疫苗組合物
ZA201600241B (en) Water-resistant composition
PL2956010T3 (pl) Kompozycja tłuszczów
GB201305984D0 (en) Mechanical linkage
EP2819668A4 (en) COMPOSITIONS OF RITONAVIR
IL245200B (en) Automatic image maker
GB201311067D0 (en) Dual curable composition
HK1219054A1 (zh) 粘膜疫苗組合物
GB2535880B (en) Two-part set-delayed cement compositions
EP3000328A4 (en) FAT COMPOSITION
GB201319923D0 (en) Novel composition
GB201310513D0 (en) Novel composition
SG11201600573VA (en) Curable compositions
SG11201604345VA (en) Phenol composition
PL2476734T3 (pl) Przezroczysty stały marker